Braden Parker
Corporate Officer/Principal bei ORCHARD THERAPEUTICS PLC
Profil
Braden Parker is currently the Chief Commercial Officer at Orchard Therapeutics Plc.
Previously, he worked as the Vice President & General Manager at PTC Therapeutics, Inc. He completed his undergraduate degree at the University of Notre Dame and holds an MBA from The Leonard N Stern School of Business.
Aktive Positionen von Braden Parker
| Unternehmen | Position | Beginn |
|---|---|---|
| ORCHARD THERAPEUTICS PLC | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Braden Parker
| Unternehmen | Position | Ende |
|---|---|---|
| PTC THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Ausbildung von Braden Parker
| The Leonard N Stern School of Business | Masters Business Admin |
| University of Notre Dame | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PTC THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
